All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the nutrition placebo controls and reported either no change or a worsening of symptoms. diet Wilcoxon-Rank of .002 for the end-points of sneezing, nutrition nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. and In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five diet and nutrition patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

In and January 1997, 62 subjects who had been the placebos in the 1995 diet study were invited to receive the vitamin B12. In June 1997, the nutrition 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy and and diet (hay fever) symptoms this spring to the last two springs? 20 nutrition people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios and - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer diet patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice daily subjects maintained a nine-week diary on sneezing, nutrition and and runny nose, nasal congestion, itchy diet eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment nutrition period, the active group (n=15) recorded and on average a greater diet reduction in symptoms and in nutrition antihistamine use than the placebo and and diet group (n=9). The results yielded reductions (0.1>p>0.01) in total nutrition and and weekly symptom/rescue medication for the active group compared to the placebo for diet and nutrition and and weeks diet 2, 6, 8 and 9. The results tend to replicate those of the studies on injectable cyanocobalamin.10